Search
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. … In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects.
Pentaerythritol tetranitrate
go.drugbank.com/drugs/DB06154ApprovedWithdrawnThe reacting solution is chilled to precipitate the PETN. … It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395].
Synonyms: TEN, Tetranitrato de pentaeritritiloAcetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawnAcetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid[L1702] and it is the first monomeric ionic compound used as an X-ray contrast agent. … [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration
Synonyms: HuMax-TF-ADCSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life.
Categories: Sphingosine 1-phosphate Receptor Modulator, Sphingosine 1 Phosphate Receptor ModulatorsCenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalThe prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals. … The loss of corneal sensation impairs corneal health, causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and perforation in severe cases.
Diazepam
go.drugbank.com/drugs/DB00829ApprovedIllicitInvestigationalVet approvedformulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016 [L5200]. … It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal
Products: E Pam Tab 5mg, E Pam Tab 2mgHydroflumethiazide
go.drugbank.com/drugs/DB00774ApprovedWithdrawnA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Technetium Tc-99m red blood cells
go.drugbank.com/drugs/DB09493ApprovedWithdrawnAutologous red blood cells are radiolabeled with sodium pertechnetate Tc 99m in the reaction vial. … It is suggested that _in vitro_ labelling improves the heart-to-background ratio during imaging [A32181].
Synonyms: Technetium Tc 99m red blood cells, Technetium Tc-99m red blood cellRemoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawn[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Categories: Dopamine D2 Receptor Antagonists